anonymous
Guest
anonymous
Guest
Here is the latest breakdown. Know one knows where the heck the HSS group is headed. Since the total vials being sold now are doing well and ahead of last year's vial number. I would think that the HSS team is brining value. It would be difficult to now think a restructuring would occur, but with that being said we know how pharma operates. The one caveat is no new product for HSS. Even though a lot of people do not want a new agent right now. It certainly gives a clearer picture of what the HSS team would be doing for the next few years.
I would think that if nothing is hinted at the NSM, and nothing comes through by q1, that creates a lot of speculation and uneasiness.
I would think that a change in some form would happen before end of Q2. Just in time for summer- remember when OSS was let go.
Signed- MM
I would think that if nothing is hinted at the NSM, and nothing comes through by q1, that creates a lot of speculation and uneasiness.
I would think that a change in some form would happen before end of Q2. Just in time for summer- remember when OSS was let go.
Signed- MM